Today Biomerica Inc (NASDAQ:BMRA) Reported Decrease in Shorted Shares

June 21, 2018 - By Hannah Black

Biomerica, Inc. (NASDAQ:BMRA) Logo

Investors sentiment decreased to 0.5 in Q1 2018. Its down 0.50, from 1 in 2017Q4. It dropped, as 4 investors sold Biomerica, Inc. shares while 0 reduced holdings. 0 funds opened positions while 2 raised stakes. 105,017 shares or 4.38% less from 109,831 shares in 2017Q4 were reported.
Tower Rech Limited Liability (Trc), New York-based fund reported 3,172 shares. Wells Fargo & Mn accumulated 6,500 shares or 0% of the stock. Moreover, Vanguard Gru has 0% invested in Biomerica, Inc. (NASDAQ:BMRA). Moreover, Bancshares Of America De has 0% invested in Biomerica, Inc. (NASDAQ:BMRA) for 3,832 shares.

Since January 23, 2018, it had 4 buys, and 0 sales for $65,333 activity. CANO FRANCIS also bought $49,324 worth of Biomerica, Inc. (NASDAQ:BMRA) shares.

The stock of Biomerica Inc (NASDAQ:BMRA) registered a decrease of 19.35% in short interest. BMRA’s total short interest was 34,600 shares in June as published by FINRA. Its down 19.35% from 42,900 shares, reported previously. With 44,500 shares average volume, it will take short sellers 1 days to cover their BMRA’s short positions. The short interest to Biomerica Inc’s float is 0.58%.

The stock increased 1.35% or $0.05 during the last trading session, reaching $3.75. About 4,434 shares traded. Biomerica, Inc. (NASDAQ:BMRA) has risen 47.16% since June 21, 2017 and is uptrending. It has outperformed by 34.59% the S&P500.

Biomerica, Inc., together with its subsidiaries, develops, makes, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. The company has market cap of $32.45 million. The companyÂ’s diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; and to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It currently has negative earnings. It primarily focuses on products for gastrointestinal, food intolerances, diabetes, and esoteric tests.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: